Skip to main
GLYC
GLYC logo

GlycoMimetics (GLYC) Stock Forecast & Price Target

GlycoMimetics (GLYC) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

GlycoMimetics Inc. is demonstrating a positive outlook, as indicated by an improved fiscal year 2024 earnings per share estimate of ($0.57) compared to the prior estimate of ($0.61), reflecting a potential for reduced losses. The company's progress in the Phase 1a study of GMI-1687 shows encouraging initial safety and pharmacokinetic results, with 39% of participants displaying a clinical response and 72% showing a reduction in bone marrow blasts, suggesting the efficacy of their glycomimetic drugs. Additionally, the FDA's clearance for a protocol amendment to allow time-based analysis of overall survival further highlights the company's strategic adjustments to enhance clinical outcomes, boosting investor confidence in their ongoing research and development efforts.

Bears say

GlycoMimetics Inc. experienced higher-than-expected general and administrative expenses of $5.1 million in the first quarter of 2024, exceeding the estimate of $4.4 million, which raises concerns regarding cost management. Research and development expenses also increased to $6.0 million, surpassing the previously established estimate of $5.3 million, indicating potential inefficiencies in its operational expenditures. Additionally, the lowered earnings per share estimate to ($0.17) from ($0.14) reflects a deteriorating financial outlook, prompting a downgrade in the stock's rating and the removal of the price target due to uncertainties regarding the company's future prospects.

GlycoMimetics (GLYC) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GlycoMimetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GlycoMimetics (GLYC) Forecast

Analysts have given GlycoMimetics (GLYC) a Buy based on their latest research and market trends.

According to 8 analysts, GlycoMimetics (GLYC) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GlycoMimetics (GLYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.